ETOPOSIDE PHARMACOKINETICS IN PATIENTS WITH NORMAL AND ABNORMAL ORGAN FUNCTION

[1] BOX GEP, 1959, BIOMETRIKA, V46, P77, DOI 10.1093/biomet/46.1-2.77

[2] STUDIES OF CROSS-RESISTANCE, SYNERGISTIC COMBINATIONS AND BLOCKING OF ACTIVITY OF PLATINUM DERIVATIVES [J]. BIOCHIMIE, 1978, 60 (09) : 961 - 965

[3] COLOMBO T, 1983, P AM ASSOC CANC RES, V24, P292

[4] CREAVEN PJ, 1982, CANCER CHEMOTH PHARM, V7, P133

[5] DINCALCI M, 1982, CANCER CHEMOTH PHARM, V7, P141

[6] DINCALCI M, 1982, P AM ASSOC CANC RES, V23, P131

[7] EVANS WE, 1982, CANCER CHEMOTH PHARM, V7, P147

[8] HANDE KR, 1984, CANCER RES, V44, P379

[9] HO DHW, 1983, P AM ASSOC CANC RES, V24, P131

[10] METZLER CM, 1974, BIOMETRICS, V30, P562

[1] BOX GEP, 1959, BIOMETRIKA, V46, P77, DOI 10.1093/biomet/46.1-2.77

[2] STUDIES OF CROSS-RESISTANCE, SYNERGISTIC COMBINATIONS AND BLOCKING OF ACTIVITY OF PLATINUM DERIVATIVES [J]. BIOCHIMIE, 1978, 60 (09) : 961 - 965

[3] COLOMBO T, 1983, P AM ASSOC CANC RES, V24, P292

[4] CREAVEN PJ, 1982, CANCER CHEMOTH PHARM, V7, P133

[5] DINCALCI M, 1982, CANCER CHEMOTH PHARM, V7, P141

[6] DINCALCI M, 1982, P AM ASSOC CANC RES, V23, P131

[7] EVANS WE, 1982, CANCER CHEMOTH PHARM, V7, P147

[8] HANDE KR, 1984, CANCER RES, V44, P379

[9] HO DHW, 1983, P AM ASSOC CANC RES, V24, P131

[10] METZLER CM, 1974, BIOMETRICS, V30, P562